Synthesis and anti-tumor activity of new steroidal nuclear analogues of aragusterol A

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 6, 2003, Pages 640-645

  Mitome, Hidemichi ^a   Shinohara, Masakazu ^a   Miyaoka, Hiroaki ^a   Yamada, Yasuji ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Analogue; Anti tumor; Aragusterol A; Steroid; Synthesis

Indexed keywords

3ALPHA,7ALPHA DIHYDROXY 5 EPIARAGUSTEROL A; 5 EPIARAGUSTEROL A; 7ALPHA HYDROXYARAGUSTEROL A; ARAGUSTEROL A; CHOLIC ACID; STEROID; UNCLASSIFIED DRUG; XESTOKEROL B;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN;

EID: 14844306670     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.640     Document Type: Article

References (25)

1. Iguchi K., Fujita M., Nagaoka H., Mitome H., Yamada Y., Tetrahedron Lett., 34, 6277-6280 (1993).
2. Shimura H., Iguchi K., Yamada Y., Nakaike S., Yamagishi T., Matsumoto K., Yokoo C., Experientia, 50, 134-136 (1994).
3. Iguchi K., Shimura H., Taira S., Yokoo C., Matsumoto K., Yamada Y., J. Org. Chem., 59, 7499-7502 (1994).
4. Miyaoka H., Shinohara M., Shimomura M., Mitome H., Yano A., Iguchi K., Yamada Y., Tetrahedron, 53, 5403-5412 (1997).
5. Kobayashi J., Ishida K., Naitoh K., Shigemori H., Mikami Y., Sasaki T., J. Nat. Prod., 56, 1350-1355 (1993).
6. Kobayashi M., Chen Y.-J., Higuchi K., Aoki S., Kitagawa I., Chem. Pharm. Bull., 44, 1840-1842 (1996).
7. Fukuoka K., Yamagishi T., Ichihara T., Nakaike S., Iguchi K., Yamada Y., Fukumoto H., Yoneda T., Samata K., Ikeya H., Nanaumi K., Hirayama N., Narita N., Saijyo N., Nishio K., Int. J. Cancer, 88, 810-819 (2000).
8. Mitome H., Miyaoka H., Nakano M., Yamada Y., Tetrahedron Lett., 36, 8231-8234 (1995).
9. Mitome H., Miyaoka H., Takahashi H., Yamada Y., Bioorg. Med. Chem. Lett., 7, 691-692 (1997).
10. Charette A. B., Juteau H., J. Am. Chem. Soc., 116, 2651-2652 (1994).
11. Charette A. B., C&EN, 73, February 6, 2 (1995).
12. Charette A. B., Prescott S., Brochu C., J. Org. Chem., 60, 1081-1083 (1995).
13. Charette A. B., Juteau H., Lebel H., Molinaro C., J. Am. Chem. Soc., 120, 11943-11952 (1998).
14. Barton D. H. R., Wozniak J., Zard S. Z., Tetrahedron, 45, 3741-3754 (1989).
15. Meystre C., Frey H., Wettstein A., Miescher K., Helv. Chim. Acta, 27, 1815-1824 (1944).
16. In this reaction, 7β-isomer was not obtained.
17. Screttas C. G., J. Chem. Soc., Chem. Commun., 1972, 752-753 (1972).
18. Freeman P. K., Hutchinson L. L., J. Org. Chem., 45, 1924-1930 (1980).
19. 13C-NMR spectrum.
20. Sharpless K. B., Michaelson R. C., J. Am. Chem. Soc., 95, 6136-6137 (1973).
21. Diastereoselectivity in the epoxidation of 14 and 17 can be explained based on the transition state in which vanadium metal is coordinated with hydroxy group at C-12. See ref. 8.
22. Fukuyama T., Akasaka K., Karanewsky D. S., Wang C.-L. J., Schmidt G., Kishi Y., J. Am. Chem. Soc., 101, 262-263 (1979).
23. The stereoselectivity of epoxidation with mCPBA is explained by preferential attack of the reagent from the less hindered side. See ref. 8.
24. On a larger scale, this procedure will sometimes lead to violent explosions. See ref. 12 and 13.
25. 2 was prepared by using Sharpless's procedure. See: Gao Y., Hanson R. M., Klunder J. M., Ko S. Y., Masamune H., Sharpless K. B., J. Am. Chem. Soc., 109, 5765-5780 (1987).